a, a N Clinical Trials

A listing of a, a N clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1890 clinical trials
Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 (COVID-19) During Pregnancy

The study evaluates the distribution of immunological and virological profiles of newborns patients. Mothers of these children have a proven infection to SARS Cov-2 during pregnancy.

covid-19
acute respiratory syndrome (sars)
SARS
maternal transmission
  • 0 views
  • 19 Feb, 2024
Enteral Feeding and Splanchnic NIRS Values in Infants With Neonatal Encephalopathy (NE)

The team will monitor splanchnic NIRS values and compare these values to a group of historic infants who underwent hypothermia but did not receive feeds, to investigate whether there may be a range of values that can predict safe feeding.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC

This study is a prospective, single-center, open-label, phase II clinical study for patients with recurrent or metastatics quamous cell carcinoma of the head and neck.

anticoagulants
stereotactic body radiation therapy
measurable disease
head and neck carcinoma
aptt
  • 0 views
  • 19 Feb, 2024
Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

A prospective, single-arm, multicenter, exploratory study to evaluate the efficacy and safety of D-CLAG regimen in the treatment of relapsed or refractory acute myeloid leukemia

granulocyte colony stimulating factor
refractory acute myeloid leukemia (aml)
clag regimen
decitabine
remission
  • 0 views
  • 19 Feb, 2024
Do We Need to Taper Down Steroid Therapy for Bell's Palsy

Tapering must be done carefully to avoid both recurrent activity of the underlying disease and possible cortisol deficiency resulting from hypothalamic-pituitary-adrenal axis (HPA) suppression. However, according to a review by Furst et al (2019), a patient who has received any dose of glucocorticoid for less than 3 weeks or patients …

  • 0 views
  • 19 Feb, 2024
Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients

This study evaluates Idarubicin (IDA) in combination with the intermediate-dose cytarabine, compared with intermediate-dose cytarabine alone, as a consolidation treatment for elderly AML in first remission.

arrhythmia
idarubicin
induction chemotherapy
heart failure
remission
  • 0 views
  • 19 Feb, 2024
Evaluation of Post Operative Pain in Retreatment of Molars Using Different Irrigant

This study evaluates the efficacy of dexamethasone as a intracanal irrigant along with sodium hypochlorite 1% and 5.25% concentrations in post treatment pain for molar root canal retreatment.

root canal
  • 0 views
  • 19 Feb, 2024
Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension

A Randomized, Double-blind, Multicenter, Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypertension

hypertension
amlodipine
irbesartan
essential hypertension
  • 0 views
  • 19 Feb, 2024
Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

Resectable, locally advanced NSCLC with involvement of mediastinal lymph nodes (N2) is associated with a high risk of (systemic) recurrence despite neo-adjuvant chemotherapy. Neo-adjuvant immunotherapy is a promising additional treatment modality aiming at increasing local control and better tackling micrometastases at the time of radical local treatment.

small cell lung cancer
large cell carcinoma
combined modality therapy
lung cancer
neutrophil count
  • 0 views
  • 19 Feb, 2024
NUVOLA TRIAL Open-label Multicentre Study

Combination of intermittent olaparib with weekly carboplatin and paclitaxel might achieve a higher pathological response rate, with an acceptable toxicity profile.

parp inhibitor
estimated creatinine clearance
luteinizing hormone
non-melanoma skin cancer
platelet count
  • 0 views
  • 19 Feb, 2024